ArticleFrontiers in immunology2026
Poly-IgA immune complex as a monitoring biomarker of response to telitacicept in IgA nephropathy.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Layered immune biomarker monitoring in IgA nephropathy: from mucosal IgA dysregulation to precision therapeutic response assessment.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunoglobulin A nephropathy (IgAN) is a common immune-mediated kidney disease. Its pathogenesis involves dysregulated B cell activation, excessive production of galactose-deficient immunoglobulin A1 (Gd-IgA1), and formation of IgA immune complex, which collectively drive glomerular injury. Telitacicept, a fusion protein that blocks B cell activation pathways, may counteract these mechanisms, but observational data and reliable biomarkers of therapeutic response remain limited. Objective: This study aimed to evaluate the clinical efficacy and safety of telitacicept and to determine whether changes in circulating B cell activating factor (BAFF), a proliferation-inducing ligand (APRIL), and Poly-IgA immune complex (Poly-IgA) reflect treatment response. Methods: In this single-center retrospective cohort study, 38 adult patients with IgAN received telitacicept combined with low-dose glucocorticoids for up to 9 months. Clinical outcomes, renal function, and safety events were monitored longitudinally, and serum biomarkers were analyzed to assess associations with remission. Results: Telitacicept treatment resulted in a substantial and sustained reduction in proteinuria while maintaining stable renal function, with over half of patients achieving complete or partial remission at 3 months. All three biomarkers reduced with treatment, and Poly-IgA showed the strongest correlation with clinical remission and the best ability to distinguish remission from non-remission. Conclusion: Telitacicept is an effective and well tolerated drug in the treatment of IgAN, with immunomodulatory effects consistent with suppression of pathogenic B cell activity. The lower level of Poly-IgA during treatment is significantly associated with clinical remission.It may serve as a promising biomarker for monitoring treatment response in the future, supporting its potential use in guiding individualized therapy for patients with IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.